A Phase 1/2 Study of AEB1102 in Patients With Arginase 1 Deficiency
A Phase 1/2 Open-label Study in Patients With Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102
A Phase 1/2 Open-label Study in Patients with Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102. This study is designed to evaluate the safety and tolerability of IV administration of AEB1102 for the treatment of pediatric and adult patients with Arginase 1 deficiency and hyperargininemia. This study will be conducted in 2 parts: Part 1 (Single Ascending Dose Escalation) and Part 2 (Repeated Dosing). Each part will be preceded by a baseline assessment of arginine levels. All patients who participate in Part 1 may continue AEB1102 dosing in Part 2 if they qualify for continued dosing. A data safety monitoring board (DSMB) will provide independent review of study safety data and recommend whether the sponsor should continue the study as planned, modify the study protocol, or discontinue the study.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
Stanford、California、アメリカ、94305
- Stanford University School of Medicine
-
-
Florida
-
Gainesville、Florida、アメリカ、32611
- University of Florida
-
-
Michigan
-
Detroit、Michigan、アメリカ、48201
- Children's Hospital of Michigan
-
-
New York
-
New York、New York、アメリカ、10029
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- UTSW
-
-
Washington
-
Seattle、Washington、アメリカ、98105
- Seattle Children's Hospital
-
-
-
-
-
London、イギリス
- Great Ormond Street Hospital
-
-
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Porto、ポルトガル
- Centro Hospitalar S. Joao
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female ≥ 2 years
- Documented diagnosis of Arginase 1 deficiency
- Adequate organ function as defined by laboratory assessment
- If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment
- If a sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration
- Patient or legal guardian is able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification) prior to any screening procedures
Exclusion Criteria:
- Transfusion of ≥ 2 units of RBCs within 60 days
- Active infection requiring systemic treatment
- Known infection with HIV, Hep B or Hep C
- Unstable hyperammonemia requiring hospitalization within 14 days
- Has a history of hypersensitivity to PEG or any other component of the AEB1102 (Co-ArgI-PEG) formulation
- If female, is lactating or breast feeding
PART 2 INCLUSION CRITERION:
1. Did not experience any safety or tolerability event in Part 1 which would preclude continued participation and dosing of AEB1102
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:AEB1102
AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks. Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy. |
modified human arginase I
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Adverse Events Related to ECGs
時間枠:Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
The primary means of assessing ECG results was through assessing AEs related to ECGs. |
Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
|
Number of Participants With Adverse Events Related to Clinical Laboratory Results
時間枠:Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
The primary means of assessing clinical laboratory results was through assessing AEs related to clinical laboratory results. Laboratory studies included hematology, chemistry, urinalysis, and coagulatio. |
Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pharmacokinetic Profile of IV AEB1102: Time of the Maximum Observed Concentration (Tmax)
時間枠:After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Area Under the Curve Through the Time of the Last Measurable Concentration (AUC0-t)
時間枠:After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Maximum Observed Concentration (Cmax)
時間枠:After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Apparent Terminal Elimination Half-life (T1/2)
時間枠:After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Area Under the Curve Extrapolated to Infinity (AUC0-∞)
時間枠:After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Serum Clearance (CL)
時間枠:After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Volume of Distribution (Vss)
時間枠:After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Plasma Arginine Concentrations After AEB1102 IV
時間枠:168 hrs post dose, Part 2: Change from Baseline to 8 weeks
|
Plasma arginine concentration post dose AEB1102 IV |
168 hrs post dose, Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: Guanidinoacetic Acid (GAA)
時間枠:Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: α-keto-δ-guanidinovaleric Acid (GVA)
時間枠:Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: Argininic Acid (ARGA)
時間枠:Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: N-α-acetyl-L-arginine (NAA)
時間枠:Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- スタディディレクター:Mattias Rudebeck, PhD MSc BMedSc、Immedica Pharma AB
出版物と役立つリンク
一般刊行物
- Diaz GA, Schulze A, McNutt MC, Leao-Teles E, Merritt JL 2nd, Enns GM, Batzios S, Bannick A, Zori RT, Sloan LS, Potts SL, Bubb G, Quinn AG. Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency. J Inherit Metab Dis. 2021 Jul;44(4):847-856. doi: 10.1002/jimd.12343. Epub 2021 Jan 26.
- Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. Mol Genet Metab. 2005 Mar;84(3):243-51. doi: 10.1016/j.ymgme.2004.11.004. Epub 2004 Dec 19.
- Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, Curley SA. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol. 2011 Jun;4(3):138-46. doi: 10.1593/tlo.10265. Epub 2011 Jun 1.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (推定)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- CAEB1102-101A
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。